Puma Biotechnology Q3 2026 net income falls 32% to $6 million
PBYI•Puma Biotechnology’s third-quarter 2026 net income fell 32% year over year to $6 million as revenue rose to $55.1 million. The company raised full-year net income guidance to $20 million–$22 million from $17 million–$20 million.
1. Quarterly results and guidance
Puma Biotechnology reported third-quarter 2026 net income of $6 million, down 32% year over year, while total revenue rose to $55.1 million. Research and development expenses increased 15% to $18.3 million, and cash provided by operating activities jumped 51% to $14.6 million. The company raised its 2026 net income guidance to $20 million–$22 million from $17 million–$20 million.
2. Lung cancer trial
During the quarter, Puma initiated ALISCA-Lung2, a Phase II trial evaluating alisertib with paclitaxel in advanced small cell lung cancer.
